Curbing the hepatitis C virus epidemic in Pakistan: The impact of scaling up treatment and prevention for achieving elimination

International Journal of Epidemiology

Volumn 47, Issue 2, 2018, Pages 550-560

  Lim, Aaron G ^a   Qureshi, Huma ^b   Mahmood, Hassan ^b,c   Hamid, Saeed ^d   Davies, Charlotte F ^a   Trickey, Adam ^a   Glass, Nancy ^e   Saeed, Quaid ^f   Fraser, Hannah ^a   GWalker, Josephine ^a   Mukandavire, Christinah ^a   Hickman, Matthew ^a   Martin, Natasha K ^a,g   May, Margaret T ^a   Averhoff, Francisco ^e   Vickerman, Peter ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b Pakistan Medical and Research Council   (Pakistan)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d AGA KHAN UNIVERSITY   (Pakistan)

^e CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^f National AIDS Control Program   (Pakistan)

^g UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Direct acting antivirals; Incidence; LMIC; Mathematical model; Mortality; Prevention

Indexed keywords

INTERFERON; RIBAVIRIN; ANTIVIRUS AGENT;

DISEASE CONTROL; DISEASE INCIDENCE; DISEASE PREVALENCE; DISEASE TRANSMISSION; DISEASE TREATMENT; EPIDEMIC; HEALTH SURVEY; HEPATITIS; INFECTIOUS DISEASE; MORTALITY; VIRUS; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADULT; ANTIVIRAL THERAPY; ARTICLE; BLOOD DONOR; CHILD; COMBINATION DRUG THERAPY; DEATH; EPIDEMIC; EPIDEMIOLOGICAL DATA; FEMALE; HEALTH SURVEY; HEPATITIS C; HUMAN; INCIDENCE; INFANT; INFECTION PREVENTION; INFECTION RISK; INTRAVENOUS DRUG ABUSE; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; NEWBORN; PAKISTAN; PREVALENCE; PRIORITY JOURNAL; SCALE UP; VIRAL CLEARANCE; VIRUS TRANSMISSION; WORLD HEALTH ORGANIZATION; AGED; CHRONIC DISEASE; DEVELOPING COUNTRY; EPIDEMIOLOGY; MIDDLE AGED; MORTALITY; PRESCHOOL CHILD; THEORETICAL MODEL; VERY ELDERLY; YOUNG ADULT;

PAKISTAN;

HEPATITIS C VIRUS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; DEVELOPING COUNTRIES; EPIDEMICS; FEMALE; HEPATITIS C; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; MODELS, THEORETICAL; PAKISTAN; WORLD HEALTH ORGANIZATION; YOUNG ADULT;

EID: 85051852286     PISSN: 03005771     EISSN: 14643685     Source Type: Journal    
DOI: 10.1093/ije/dyx270     Document Type: Article

References (41)

1. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 2014;61(Suppl 1):S45-57
2. World Health Organization. Global Hepatitis Report, 2017. Geneva: WHO, 2017
3. Graham CS, Swan T. A path to eradication of hepatitis C in lowand middle-income countries. Antiviral Res 2015;119:89-96
4. World Health Organization. Guidelines for the Screening Care and Treatment of Persons with Chronic Hepatitis C Infection: Updated Version. Geneva: World Health Organization, 2016
5. World Health Organization. Global Health Sector Strategy on Viral Hepatitis 2016-2021. Towards Ending Viral Hepatitis. Geneva: WHO, 2016
6. Janjua NZ, Hamza HB, Islam M et al. Health care risk factors among women and personal behaviours among men explain the high prevalence of hepatitis C virus infection in Karachi, Pakistan. J Viral Hepat 2010;17:317-26
7. Qureshi H, Bile KM, Jooma R, Alam SE, Afridi HUR. Prevalence of hepatitis B and C viral infections in Pakistan: findings of a national survey appealing for effective prevention and control measures. East Mediterr Health J 2010;16(Suppl): S15-23
8. Waheed Y, Shafi T, Safi SZ, Qadri I. Hepatitis C virus in Pakistan: a systematic review of prevalence, genotypes and risk factors.World J Gastroenterol 2009;15:5647-53
9. Centers for Disease Control and Prevention (CDC). Establishment of a viral hepatitis surveillance system, Pakistan, 2009-2011. MMWR Morb Mortal Wkly Rep 2011;60(40): 1385-90
10. Krishanani MK, Qidwai W, Ali BS, Khuwaja AK. Educational intervention among barbers about liver cancer-inducing viruses: a pilot study from a developing country. J Cancer Educ 2010;25: 632-36
11. European Union HCV Collaborators. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. Lancet Gastroentero Hepatol 2017;2:325-36
12. Hatzakis A, Chulanov V, Gadano AC et al. The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm. Vol. 2. J Viral Hepat 2015; 22(Suppl 1):26-45
13. Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol 2017;2:161-76
14. Razavi H, Waked I, Sarrazin C et al. The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J Viral Hepat 2014;21(Suppl 1):34-59
15. Sibley A, Han KH, Abourached A et al. The present and future disease burden of hepatitis C virus infections with today's treatment paradigm. Vol. 3. J Viral Hepat 2015;22(Suppl 4):21-41
16. Ayoub HH, Abu-Raddad LJ. Impact of treatment on hepatitis C virus transmission and incidence in Egypt: A case for treatment as prevention. J Viral Hepat 2016;24:486-95
17. Breban R, Arafa N, Leroy S et al. Effect of preventive and curative interventions on hepatitis C virus transmission in Egypt (ANRS 1211): a modelling study. Lancet Global Health 2014;2: e541-49
18. Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol 2014;61(Suppl 1):S58-68
19. Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med 2013;158(Pt 1):329-37
20. United Nations, Department of Economic and Social Affairs, Population Division. United Nations World Population Prospects: The 2015 Revision. https://esa.un.org/unpd/wpp/ (30 June 2016, date last accessed)
21. United Nations Office on Drugs and Crime. Drug Use in Pakistan 2013. http://www.unodc.org (30 June 2016, date last accessed)
22. Nelson PK, Mathers BM, Cowie B et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 2011;378:571-83
23. Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat 2006;13:34-41
24. Trickey A, May MT, Davies C et al. Importance and contribution of community, social, and healthcare risk factors for hepatitis C Infection in Pakistan. Am J Trop Med Hyg 2017;97: 1920-28
25. Thein H-H, Yi Q, Dore GJ, Krahn MD. Estimation of stagespecific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 2008; 48:418-31
26. Nishtar S. Health Indicators of Pakistan. Gateway Paper II. Islamabad: Federal Bureau of Statistics and Ministry of Health, 2007
27. Pakistan Medical Research Council. National Health Survey of Pakistan: Health Profile of the People of Pakistan, 1990-94. Islamabad: Pakistan Medical Research Council, 1998
28. Pakistan Medical Research Council, Directorate of Malaria Control, Save The Children. Malaria Indicator Survey in 38 High Risk Districts of Pakistan 2013-2014. Islamabad: PMRC, 2015
29. Regional Health Systems Observatory, World Health Organization. Health System Profile 2007-Pakistan. Geneva: WHO, 2008
30. Qureshi H, Mohamud BK, Alam SE, Arif A, Ahmed W. Treatment of hepatitis B and C through national programme-an audit. J Pak Med Assoc 2013;63:220-24
31. Umar M, Bilal M. Hepatitis C, a mega menace: a Pakistani perspective. J Pioneer Med Sci 2012;2:68
32. World Health Organization. Global Report on Access to Hepatitis C Treatment. Geneva: WHO, 2016
33. National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Population Health and Public Health Practice; Committee on a National Strategy for the Elimination of Hepatitis B and C. A National Strategy for the Elimination of Hepatitis B and C. Washington, DC: National Academies Press, 2017
34. World Health Organization. Combating Hepatitis B and C to Reach Elimination by 2030: Advocacy Brief. Geneva: WHO, 2016
35. Gvinjilia L, Nasrullah M, Sergeenko D et al. National progress toward hepatitis C elimination-Georgia, 2015-2016. MMWR Morb Mortal Wkly Rep 2016;65:1132-35
36. Platt L, Reed J, Minozzi S et al. Effectiveness of needle/syringe programmes and opiate substitution therapy in preventing HCV transmission among people who inject drugs. Cochrane Database Syst Rev 2016;2016:CD012021
37. Platt L, Minozzi S, Reed J et al. Needle syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and meta-analysis. Addiction 2017, Sep 11. doi: 10.1111/add.14012
38. Cousien A, Tran VC, Deuffic-Burban S, Jauffret-Roustide M, Dhersin JS, Yazdanpanah Y. Dynamic modelling of hepatitis C virus transmission among people who inject drugs: a methodological review. J Viral Hepat 2015;22:213-29
39. Martin NK, Vickerman P, Grebely J et al. Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. Hepatology 2013;58:1598-609
40. Martin NK, Vickerman P, Dore GJ, HickmanM. The hepatitis C virus epidemics in key populations (including people who inject drugs, prisoners and MSM): the use of direct-acting antivirals as treatment for prevention. Curr Opin HIVAIDS 2015;10:374-80
41. Kandeel A, Genedy M, El-Refai S, Funk AL, Fontanet A, Talaat M. The prevalence of hepatitis C virus infection in Egypt 2015: implications for future policy on prevention and treatment. Liver Int 2017;37:45-53